Topic: Failed drug program
An audit of Celgene’s R&D over the last five years has revealed that two-thirds of its programs failed.
Celldex culled another two R&D projects after its midstage failure in April, and now says it will focus its efforts mainly on two cancer antibodies.
Both drugs held up as the drivers for Allergan’s $639 million purchase of Vitae have now been dropped.
ADC Therapeutics has dropped a midpipeline candidate for HER2-positive cancers because of toxicity issues in a phase 1 trial in solid tumors.
The antibiotic cadazolid was one of two experimental assets J&J acquired in its $30 billion takeover of Actelion last year.
Hanmi Pharmaceutical’s long and turbulent development of lung cancer drug olmutinib finally came to an end this week.
Inhaled sodium nitrite missed both primary and secondary objectives in heart failure patients with preserved ejection fraction.
The decision follows data from two phase 2 trials that tested angiopoietin 2 antibody nesvacumab in combination with Eylea.
Unexpected side effects have spelled the end for Ardelyx’s drug candidate to treat elevated potassium levels in the blood, which was in phase 3 testing.
Cytokinetics canned tirasemtiv after it failed to beat placebo against the primary endpoint or any of the secondary goals in an ALS trial.